Cargando…

Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease

BACKGROUND: Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases (AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species. This is necessary for maintenance of tissue homeostasis and host defense,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pey, Peixuan, Pearce, Ronald KB, Kalaitzakis, Michail E, Griffin, W Sue T, Gentleman, Steve M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940003/
https://www.ncbi.nlm.nih.gov/pubmed/24528486
http://dx.doi.org/10.1186/2051-5960-2-21
_version_ 1782305763961602048
author Pey, Peixuan
Pearce, Ronald KB
Kalaitzakis, Michail E
Griffin, W Sue T
Gentleman, Steve M
author_facet Pey, Peixuan
Pearce, Ronald KB
Kalaitzakis, Michail E
Griffin, W Sue T
Gentleman, Steve M
author_sort Pey, Peixuan
collection PubMed
description BACKGROUND: Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases (AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species. This is necessary for maintenance of tissue homeostasis and host defense, but can cause bystander damage when the activation is sustained and uncontrolled. In recent years the heterogeneous nature of microglial activation states in neurodegenerative diseases has become clear and the focus has shifted to alternative activation states that promote tissue maintenance and repair. We studied the distribution of CD163, a membrane-bound scavenger receptor found on perivascular macrophages. CD163 has an immunoregulatory function, and has been found in the parenchyma in other inflammatory diseases e.g. HIV-encephalitis and multiple sclerosis. In this study, we used immunohistochemistry to compare CD163 immunoreactivity in 31 AD cases, 27 PD cases, and 16 control cases. Associations of microglia with pathological hallmarks of AD and PD were investigated using double immunofluorescence. RESULTS: Parenchymal microglia were found to be immunoreactive for CD163 in all of the AD cases, and to a lesser extent in PD cases. There was prominent staining of CD163 immunoreactive microglia in the frontal and occipital cortices of AD cases, and in the brainstem of PD cases. Many of them were associated with Aß plaques in both diseases, and double staining with CD68 demonstrates their phagocytic capability. Leakage of fibrinogen was observed around compromised blood vessels, raising the possibility these microglia might have originated from the periphery. CONCLUSIONS: Increase in microglia’s CD163 immunoreactivity was more significant in AD than PD, and association of CD163 immunoreactive microglia with Aβ plaques indicate microglia’s attraction towards extracellular protein pathology, i.e. extracellular aggregates of Aβ as compared to intracellular Lewy Bodies in PD. Double staining with CD163 and CD68 might point towards their natural inclination to phagocytose plaques. Fibrinogen leakage and compromise of the blood brain barrier raise the possibility that these are not resident microglia, but systemic macrophages infiltrating the brain.
format Online
Article
Text
id pubmed-3940003
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39400032014-03-04 Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease Pey, Peixuan Pearce, Ronald KB Kalaitzakis, Michail E Griffin, W Sue T Gentleman, Steve M Acta Neuropathol Commun Research BACKGROUND: Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases (AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species. This is necessary for maintenance of tissue homeostasis and host defense, but can cause bystander damage when the activation is sustained and uncontrolled. In recent years the heterogeneous nature of microglial activation states in neurodegenerative diseases has become clear and the focus has shifted to alternative activation states that promote tissue maintenance and repair. We studied the distribution of CD163, a membrane-bound scavenger receptor found on perivascular macrophages. CD163 has an immunoregulatory function, and has been found in the parenchyma in other inflammatory diseases e.g. HIV-encephalitis and multiple sclerosis. In this study, we used immunohistochemistry to compare CD163 immunoreactivity in 31 AD cases, 27 PD cases, and 16 control cases. Associations of microglia with pathological hallmarks of AD and PD were investigated using double immunofluorescence. RESULTS: Parenchymal microglia were found to be immunoreactive for CD163 in all of the AD cases, and to a lesser extent in PD cases. There was prominent staining of CD163 immunoreactive microglia in the frontal and occipital cortices of AD cases, and in the brainstem of PD cases. Many of them were associated with Aß plaques in both diseases, and double staining with CD68 demonstrates their phagocytic capability. Leakage of fibrinogen was observed around compromised blood vessels, raising the possibility these microglia might have originated from the periphery. CONCLUSIONS: Increase in microglia’s CD163 immunoreactivity was more significant in AD than PD, and association of CD163 immunoreactive microglia with Aβ plaques indicate microglia’s attraction towards extracellular protein pathology, i.e. extracellular aggregates of Aβ as compared to intracellular Lewy Bodies in PD. Double staining with CD163 and CD68 might point towards their natural inclination to phagocytose plaques. Fibrinogen leakage and compromise of the blood brain barrier raise the possibility that these are not resident microglia, but systemic macrophages infiltrating the brain. BioMed Central 2014-02-14 /pmc/articles/PMC3940003/ /pubmed/24528486 http://dx.doi.org/10.1186/2051-5960-2-21 Text en Copyright © 2014 Pey et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pey, Peixuan
Pearce, Ronald KB
Kalaitzakis, Michail E
Griffin, W Sue T
Gentleman, Steve M
Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title_full Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title_fullStr Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title_full_unstemmed Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title_short Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease
title_sort phenotypic profile of alternative activation marker cd163 is different in alzheimer’s and parkinson’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940003/
https://www.ncbi.nlm.nih.gov/pubmed/24528486
http://dx.doi.org/10.1186/2051-5960-2-21
work_keys_str_mv AT peypeixuan phenotypicprofileofalternativeactivationmarkercd163isdifferentinalzheimersandparkinsonsdisease
AT pearceronaldkb phenotypicprofileofalternativeactivationmarkercd163isdifferentinalzheimersandparkinsonsdisease
AT kalaitzakismichaile phenotypicprofileofalternativeactivationmarkercd163isdifferentinalzheimersandparkinsonsdisease
AT griffinwsuet phenotypicprofileofalternativeactivationmarkercd163isdifferentinalzheimersandparkinsonsdisease
AT gentlemanstevem phenotypicprofileofalternativeactivationmarkercd163isdifferentinalzheimersandparkinsonsdisease